At a National Assembly group session on the morning of 21/10, discussing several health-sector draft laws, Prime Minister Lê Minh Hưng said medicines and medical equipment have been overpriced due to too many intermediary steps, causing major losses for patients, the state budget and the Health Insurance Fund. Inspections and investigations found many loopholes in laws, circulars and implementation, including a case involving Công ty cổ phần Đầu tư y tế Việt Mỹ, where multiple foreign companies traded goods among themselves, inflating prices and evading taxes. The government proposes urgent amendments to cut intermediaries, increase transparency, and set different procurement mechanisms: centralized bidding for common goods and direct negotiation for specialized items. The Prime Minister stressed that businesses may earn reasonable profits, but the State must control this sensitive sector.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Thủ tướng: Thuốc, thiết bị y tế bị đội giá cao gây thiệt hại lớn cho cả người bệnh và Nhà nước
Keywords
healthcarepharmaceuticalsVietnam
Open a keyword to see other news on the same topic.
Related tickers and likely impact
IMP
▼ Likely negativeImexpharm Pharma
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Market cap | 5,490 bn VND |
| P/E | 15.2 |
| P/B | 2.44 |
| Close on 10/20/2026 | 35.65 |
| Change that session | +0.28% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam shares have fallen more than 40% year to date, even though the company is now solidly profitable, with Q2 2026 GAAP net income of $164.5 million and revenue up 67% to $1.29 billion. The author attributes much of the selloff to two concerns: Alnylam cut its 2026 revenue guidance for Amvuttra and Onpattra to $4.2–4.5 billion from $4.4–4.7 billion as demand normalized after an initial surge of patients switching to Amvuttra, and disappointing Phase 3 results for Wainua in ATTR-CM raised worries about Alnylam's nucresiran. The author argues both concerns are overstated, since the two drugs use different mechanisms and Amvuttra sales continue to grow robustly. Of the 23 analysts who rated the stock over the past three months, 19 recommended buying, and the average 12-month price target implies 54% upside.
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison pits Amgen (AMGN) against Bristol Myers Squibb (BMY), with Amgen focused on biologics and BMY strong in oncology and hematology. In FY 2025, Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion, a net margin near 21%, and free cash flow of nearly $8.1 billion. BMY generated revenue of about $48.2 billion, nearly flat, with net income of about $7.1 billion, a net margin near 14.6%, and free cash flow of about $12.8 billion. Amgen faces drug pricing pressure, an IRS tax dispute and biosimilar competition, while BMY relies heavily on Eliquis, which faces generic competition. The article describes BMY as cheaper, but says much of the difficulty appears priced in, so it is not an obvious buy right now.
Related markets
Latest news
- BlackBerry Jumps 6% as Record QNX Backlog Extends Rally, Now Up 149% YTD; Mobileye Drops 4%, Aptiv Dips
BlackBerry stock rose 6% to $9.45 in afternoon trading after the company said its QNX unit’s royalty backlog exceeded $1.2 billion, a record, and the stock is up 149% year to date. Management credited growing adoption of the QNX Software Development Platform and the first deal for Alloy Kore, which it called the largest design win in QNX’s history, along with wins in robotics, industrial automation and medical devices. Over the same period, Mobileye fell 4% to $7 and Aptiv slipped 0.6% to $44.79, while the Global X Autonomous & Electric Vehicles ETF rose 0.1%. The article explains that QNX earns licensing royalties as vehicle programs enter production, whereas Mobileye and Aptiv carry heavier hardware content. The key question now is whether the backlog converts into royalty revenue on schedule, which depends on when automakers move programs into production.
- On October 22, how much interest would 100 million VND earn after 24 months at 7 banks?
Based on listed rates for a 24-month term with interest paid at maturity, VPBank offers the highest counter rate at 6.9% per year (VND 13.8 million in interest), followed by MB at 6.5% (VND 13 million) and Sacombank at 6.2% (VND 12.4 million). Techcombank has the lowest counter rate in the compared group at 4.85% per year, or VND 9.7 million. For online deposits, Sacombank leads at 7.3% per year (VND 14.6 million), followed by VPBank at 7.1% (VND 14.2 million), while HDBank pays 5% (VND 10 million) and Techcombank 5.35% (VND 10.7 million); ACB has no 24-month online rate data. The rates are compiled from bank rate schedules, apply to specific products and deposit amounts, and may change over time or by agreement with depositors.
- TeraWulf Jumps 8% as CEO Says Power Demand Remains ‘Extremely Strong’; Applied Digital Surges 9%, IREN Climbs 6%
TeraWulf shares rose 8% to $12.95 in afternoon trading after CEO Paul B. Prager wrote on X that demand for power “remains extremely strong,” that the company’s site is “energized” to meet it, and that shareholders would not be diluted. He said customers would likely need outside funding but TeraWulf would not take on that financial risk, and that the next data center building at Lake Mariner, leased to Fluidstack, is on track for delivery this quarter. Applied Digital rose 9% to $21.17 and IREN climbed 6% to $28.11, while the CoinShares Bitcoin Mining and Digital Power ETF gained 3% to $32.43 against a 0.6% rise in the SPDR S&P 500 ETF Trust. The article links the rally to power scarcity, including Elon Musk’s comment on the earnings call that the infrastructure to supply and cool electrical equipment is “somewhat of a limiting factor” for superintelligence. The next test for TeraWulf is whether the Lake Mariner building is delivered on schedule this quarter.
- Why Pegasystems Stock Dropped After Earnings
Pegasystems shares slipped 3.6% by 1:30 p.m. ET on Wednesday after the company reported Q3 results well below analyst forecasts. Analysts expected $0.49 per share on $421.8 million in sales, but Pegasystems earned $0.35 per share on a non-GAAP basis with sales below $393.4 million, and GAAP earnings were only $0.08 per share. Sales grew 3% year over year, GAAP profit fell 68%, and annual contract value rose 6%, which CEO Alan Trefler and CFO Ken Stillwell cited as grounds for confidence. The article argues free cash flow matters more to investors: the company generated $490 million last year and is running at about $438 million annualized, and Stillwell projects $700 million or more by 2028. The article calculates that this would imply near-term free cash flow growth north of 25%.
- Salesforce (CRM) vs Oracle (ORCL): Which Is a Better Stock to Buy?
Salesforce closed at $242.45 on October 19 and gained 30.2% over six months, versus 8.7% for the State Street SPDR S&P 500 ETF Trust, while Oracle closed at $129.59 after losing more than a quarter of its value over the same period. The article describes Salesforce’s customer records and workflows as hard to replace, with $14.4 billion of free cash flow in its last fiscal year, but notes slow growth, with revenue up 10.80% last quarter, and a deal announced October 20 to buy Braze for $5.66 billion. Its seat-based pricing could be a risk if AI agents take on work that staff used to do. Oracle grew revenue 29.60% last quarter at a 35.63% operating margin, supported by database support contracts, but its build-out of AI computing capacity carries debt equal to 251.72% of equity and levered free cash flow of negative $45.85 billion over the past year. The article adds that renting computing capacity earns a thinner margin than licensing software.
- Cold Water: Tesla and SpaceX Merger “Won’t Add Much Value” per Gary Black
Gary Black, managing partner of The Future Fund, argues that an all-stock Tesla–SpaceX deal at about $420 per Tesla share, roughly 10% above the current price, would add little value. Tesla trades at 191.6x forward earnings, well above its three-year average of 135.1x and above SpaceX's multiple, so the combined company would likely be valued at SpaceX's lower level. Tesla's normalized EPS fell from $3.12 in fiscal 2023 to $1.66 in fiscal 2025, with analysts expecting $2.17 in fiscal 2027. Musk said special committees at both companies are studying the idea and that he thinks it would be a good idea, but no terms have been agreed.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.